WVWendy Vargas

Wendy Vargas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wendy Vargas has a total of 220 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tolebrutinib Phase 2b Long-Term Extension Study

    by Jiwon Oh, Robert J. Fox, Douglas L. Arnold, Sana Syed, Deborah Dukovic, Wendy S. Vargas, Timothy J. Turner, Conor F. Underwood, Tiha M. Long, Anthony L. Traboulsee, et al.

    Tolebrutinib is an oral, brain-penetrant, covalent Bruton's tyrosine kinase (BTK) inhibitor currently under investigation as a disease-modifying therapy for multiple sclerosis (MS). In a Phase 2b trial, tolebrutinib administration was generally well tolerated and produced dose-dependent reductions in new gadolinium (Gd)-enhancing T1 and new/enlarging T2 lesions in participants with relapsing MS. We evaluated the safety and effectiveness of tolebrutinib for 2 years after the end of the Phase 2b trial in a long-term safety (LTS) extension study. This is an ongoing, two-part LTS extension study conducted at academic sites, specialty clinics, and general neurology centers. Participants who completed the Phase 2b trial on treatment were eligible for enrollment. In LTS Part A, participants continued their core study tolebrutinib dose (5, 15, 30, or 60 mg/day) double-blind. In Part B, all participants switched to open-label treatment with the selected Phase 3 dose of tolebrutinib 60 mg/day taken with food. Safety (the primary objective) was measured by adverse events (AEs). Efficacy measures included new Gd-enhancing T1 lesions, new/enlarging T2 lesions, annualized relapse rate (ARR), and Expanded Disability Status Scale (EDSS) score. Of the 129 participants who completed core study treatment, 125 enrolled in LTS Part A and received tolebrutinib, 124 entered Part B, and 114 remain on study as of February 18, 2022. Mean age at core study baseline was 37.8 years and 69% of participants were female. The most common treatment-emergent AEs were COVID-19 (n=26/125, 21%) and headache (n=17/125, 14%). At LTS Week (W)96, 79% of participants assigned in the core study to 60 mg (60 mg/60 mg arm) had no new Gd-enhancing T1 lesions since the previous scan (W72), 33% had no new/enlarging T2 lesions since LTS W0, and 50% had ≤2 new/enlarging T2 lesions since LTS W0. ARR on tolebrutinib 60 mg/day for ≥8 weeks was 0.17 (95% confidence interval: 0.12, 0.25), and median EDSS scores were stable. Over 2 years, tolebrutinib showed an acceptable safety profile, with durable effects on MRI measures, ARR, and EDSS. Conclusions regarding efficacy are limited by the study's open-label design and lack of a comparator group. This study provides class IV evidence. It is an uncontrolled study without a comparator group.


  • When transfusion causes a splitting headache: A case report and rapid review of transfusion‐associated reversible cerebral vasoconstriction syndrome

    by Bobbie Pelham‐Webb, Yin Guo, Alejandra Ramirez, Evan Waldron, Valentina Emmanuele, Wendy Vargas, Justine Kahn, Elizabeth F. Stone

    KEY IDEAS: Reversible cerebral vasoconstriction syndrome (RCVS) is a rare and understudied transfusion reaction most commonly seen in adult females after correction of chronic, severe anemia. Transfusion‐associated RCVS (TA‐RCVS) typically presents with thunderclap headaches and one or more systemic (hypertension, nausea/vomiting) or neurologic (seizure, stroke, visual changes) symptoms within a week after red blood cell transfusion. Treatment of RCVS is based on blood pressure control; a recent study suggested that early use of nimodipine could shorten the disease course.


  • Open Access

    Distinct Th17 effector cytokines differentially promote microglial and blood-brain barrier inflammatory responses during post-infectious encephalitis

    by Charlotte R. Wayne, Luca Bremner, Travis E. Faust, Violeta Durán-Laforet, Nicole Ampatey, Sarah J. Ho, Philip A. Feinberg, Panos Arvanitis, Bogoljub Ciric, Chunsheng Ruan, et al.

    SUMMARY: Group A Streptococcus (GAS) infections can cause neuropsychiatric sequelae in children due to post-infectious encephalitis. Multiple GAS infections induce migration of Th17 lymphocytes from the nose into the brain, which are critical for microglial activation, blood-brain barrier (BBB) and neural circuit impairment in a mouse disease model. How endothelial cells (ECs) and microglia respond to GAS infections, and which Th17-derived cytokines are essential for these responses are unknown. Using single-cell RNA sequencing and spatial transcriptomics, we found that ECs downregulate BBB genes and microglia upregulate interferon-response, chemokine and antigen-presentation genes after GAS infections. Several microglial-derived chemokines were elevated in patient sera. Administration of a neutralizing antibody against interleukin-17A (IL-17A), but not ablation of granulocyte-macrophage colony-stimulating factor (GM-CSF) in T cells, partially rescued BBB dysfunction and microglial expression of chemokine genes. Thus, IL-17A is critical for neuropsychiatric sequelae of GAS infections and may be targeted to treat these disorders.


  • Risk Factors for New Neurologic Diagnoses in Hospitalized Patients With COVID-19 A Case-Control Study in New York City

    by Kiran T. Thakur, Victoria T. Chu, Christine Hughes, Carla Y. Kim, Shannon Fleck-Derderian, Catherine E. Barrett, Elizabeth Matthews, Alanna Balbi, Amanda Bilski, Mashina Chomba, et al.

    Background and Objectives There have been numerous reports of neurologic manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurologic symptoms and diagnoses, define the time course of their development, and examine readmission rates and mortality risk posthospitalization in a multiethnic urban cohort. Methods We identify the occurrence of new neurologic diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed on 532 cases (hospitalized patients with new neurologic diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020, and August 31, 2020). We compare demographic and clinical features of the 532 cases with 532 controls (hospitalized COVID-19 patients without neurologic diagnoses) in a case-control study with one-to-one matching and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis. Results Among the 532 cases, the most common new neurologic diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs 52.8%, p = 0.05), had baseline neurologic comorbidities (36.3% vs 13.0%, p < 0.0001), and were to be treated in an intensive care unit (62.0% vs 9.6%, p < 0.0001). Of the 394 (74.1%) cases who survived acute hospitalization, more than half (220 of 394, 55.8%) were readmitted within 6 months, with a mortality rate of 23.2% during readmission. Discussion Hospitalized patients with SARS-CoV-2 and new neurologic diagnoses have significant morbidity and mortality postdischarge. Further research is needed to define the effect of neurologic diagnoses during acute hospitalization on longitudinal post-COVID-19-related symptoms including neurocognitive impairment.


  • Potential Neurologic Manifestations of COVID-19

    by Anna S. Nordvig, Kathryn T. Fong, Joshua Z. Willey, Kiran T. Thakur, Amelia K. Boehme, Wendy S. Vargas, Craig J. Smith, Mitchell S.V. Elkind

    Purpose of Review Neurologic complications are increasingly recognized in the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This coronavirus is related to severe acute respiratory syndrome coronavirus (SARS-CoV) and other human coronavirus-related illnesses that are associated with neurologic symptoms. These symptoms raise the question of a neuroinvasive potential of SARS-CoV-2. Recent Findings Potential neurologic symptoms and syndromes of SARS-CoV-2 include headache, fatigue, dizziness, anosmia, ageusia, anorexia, myalgias, meningoencephalitis, hemorrhage, altered consciousness, Guillain-Barré syndrome, syncope, seizure, and stroke. In addition, we discuss neurologic effects of other coronaviruses, special considerations for management of neurologic patients, and possible long-term neurologic and public health sequelae. Summary As SARS-CoV-2 is projected to infect a large part of the world9s population, understanding the potential neurologic implications of COVID-19 will help neurologists and others recognize and intervene in neurologic morbidity during and after the pandemic of 2020.


  • Open Access

    Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases

    by Seth N. Levin, Shruthi Venkatesh, Katie E. Nelson, Yi Li, Ines Aguerre, Wen Zhu, Karman Masown, Kathryn T. Rimmer, Claudiu I. Diaconu, Kaho B. Onomichi, et al.

    Objective: To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS).Methods: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID‐19 in persons with NID (PwNID) and change in their neurological care.Results: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID‐19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID‐19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID‐19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID‐19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID‐19 (ORadj = 1.45, 1.17–1.84).Interpretations: Our study of real‐time, patient‐reported experience during the COVID‐19 pandemic complements physician‐reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID‐19 similar to the reference population.


  • Neuroimmunologic disorders in pregnancy

    by Seth Levin, Kathryn Rimmer, Wendy S. Vargas


  • Pediatric Inflammatory and Autoimmune Neurologic Disorders at a Tertiary Medical Center

    by Angela M. Curcio, Jennifer M. Bain, Erin S. Beck, Wendy S. Vargas

    To describe the spectrum of pediatric inflammatory neurologic diseases and compare the sensitivity of ancillary testing for these diagnoses. We analyzed clinical features and outcomes of 98 children with an immune-mediated central nervous system disorder. We compared sensitivities of each diagnostic modality. We identified the following diagnoses: acute cerebellar ataxia (n = 14; 14.3%), acute demyelinating encephalomyelitis (n = 13; 13.3%), multiple sclerosis (MS) (n = 18; 18.4%), anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDAR encephalitis) (n = 15; 15.3%), encephalitis not otherwise specified (n = 12; 12.2%), and “Other” (n = 26; 26.5%). “Other” included acute transverse myelitis, neuromyelitis optica, central nervous system lupus, primary central nervous system vasculitis, Rasmussen encephalitis, opsoclonus myoclonus ataxia syndrome, and clinically isolated syndrome. The mean age of onset of all diagnoses was 7.9 ± 5.5 years. The diagnostic sensitivity of magnetic resonance imaging (MRI) for acute demyelinating encephalomyelitis and multiple sclerosis was 92.3% and 94.4%, respectively. Cerebrospinal fluid was sensitive for multiple sclerosis in 92.3%, where 75% of patients had cerebrospinal fluid oligoclonal bands. Electroencephalogram (EEG) coupled with cerebrospinal fluid studies was highly sensitive for anti-NMDAR encephalitis (100%). EEG was sensitive for acute demyelinating encephalomyelitis and encephalitis not otherwise specified (77.8% and 80%). No diagnostic studies were sensitive for acute cerebellar ataxia. Seventy-three percent of patients with multiple sclerosis had residual deficits. Thirty-six percent of anti-NMDAR encephalitis patients were nonverbal and wheel-chair bound. We found that MRI is useful for detecting multiple sclerosis and acute demyelinating encephalomyelitis, cerebrospinal fluid is helpful in diagnosing multiple sclerosis and anti-NMDAR encephalitis, and EEG is often abnormal in suspected anti-NMDAR encephalitis, acute demyelinating encephalomyelitis, and encephalitis not otherwise specified. Neurologic outcome at follow-up was unfavorable in patients with multiple sclerosis and anti-NMDAR encephalitis.


  • Open Access

    Fatal COVID-19 in an MS patient on natalizumab: A case report

    by Kathryn Rimmer, Rebecca Farber, Kiran Thakur, Genna Braverman, Dina Podolsky, Lauren Sutherland, Christopher Migliore, Yun Kyoung Ryu, Seth Levin, Philip L De Jager, et al.

    We report a fatal case of COVID-19 in a 51-year-old African American woman with multiple sclerosis on natalizumab. She had multiple risk factors for severe COVID-19 disease including race, obesity, hypertension, and elevated inflammatory markers, but the contribution of natalizumab to her poor outcome remains unknown. We consider whether altered dynamics of peripheral immune cells in the context of natalizumab treatment could worsen the cytokine storm syndrome associated with severe COVID-19. We discuss extended interval dosing as a risk-reduction strategy for multiple sclerosis patients on natalizumab, and the use of interleukin-6 inhibitors in such patients who contract COVID-19.